Healthcare Industry News: Fragile X
News Release - July 20, 2010
Seaside Therapeutics Appoints Leading Industry Executives to its Board of DirectorsCAMBRIDGE, Mass.--(HSMN NewsFeed)--Seaside Therapeutics, Inc. today announced the appointments of Marc D. Beer, former Chief Executive Officer of ViaCell, Inc., Karen A. Dawes, President of Knowledge Decisions, LLC, and Steven M. Paul, M.D., former Executive Vice President for Science and Technology of Eli Lilly and Company, to its Board of Directors. The three new members join current board members, Randall L. Carpenter, M.D., President and Chief Executive Officer of Seaside Therapeutics, and Peter Whipp, Managing Director of Barony Trust, Ltd., a private investment company and Seaside’s largest investor.
Marc Beer brings more than 20 years of experience in general management and sales and marketing experience in the biopharmaceutical, medical device and diagnostics businesses. Mr. Beer led ViaCell, a biotechnology company focused on the application of human cells as therapeutics, as its Chief Executive Officer, ultimately negotiating its sale to PerkinElmer. Prior to ViaCell, he held a number of senior management positions at Genzyme Corporation, most recently serving as Vice President, Global Marketing for Genzyme Therapeutics. Prior to that, Mr. Beer held a variety of management roles at BioStar Inc. and Abbott Laboratories. In these combined roles, Mr. Beer led the successful commercial launch of multiple products in several therapeutic areas, including orphan drugs. He received a Bachelors of Science in Business Administration from Miami University in Ohio.
Karen Dawes brings more than 20 years of commercial and executive management experience in the biopharmaceutical industry. Ms. Dawes is currently President of Knowledgeable Decisions, a biopharmaceutical consulting firm. Previously, she served as Senior Vice President and U.S. Business Group Head for Bayer Corporation's U.S. Pharmaceuticals Group. Prior to joining Bayer, Ms. Dawes was Senior Vice President, Global Strategic Marketing at Wyeth Pharmaceutics and previously held senior level marketing and operations positions at Genetics Institute, Inc. and Pfizer, Inc. In these roles, Ms. Dawes led the successful commercial launches of numerous blockbuster products. She received a combined Bachelors and Masters in Arts from Simmons College and a Masters in Business Administration from Harvard Business School.
Steven Paul, M.D., brings more than 35 years of scientific research and general management experience in the pharmaceutical industry. He was most recently Executive Vice President for Science and Technology and President of the Lilly Research Laboratories of Eli Lilly, where he played a leading role in the development of a number of very successful commercial products, including Zyprexa®, Strattera® and Cymbalta®. Prior to joining Lilly, Dr. Paul was the scientific director of the National Institute of Mental Health. He has authored or coauthored more than 500 papers and invited book chapters and serves on the editorial boards of numerous scientific journals. He is a director of the Foundation of the National Institutes of Health and the Allen Institute for Brain Sciences, a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Association for the Advancement of Science. Dr. Paul received both a Masters of Science in anatomy and neuroanatomy and a Doctor of Medicine from Tulane University.
About Seaside Therapeutics
Seaside Therapeutics, Inc. is creating novel drug treatments to correct or improve the course of Fragile X syndrome, autism and other neurodevelopmental disorders. The Company is dedicated to translating breakthrough discoveries in neurobiology into therapeutics that improve the lives of patients and their families. For more information please visit www.seasidetherapeutics.com.
Zyprexa, Strattera and Cymbalta are registered trademarks of Lilly USA.
Source: Seaside Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.